GSK To Offer Flexible Drug Pricing In Middle-Income Countries
Main Category: Pharma Industry / Biotech IndustryArticle Date: 11 Mar 2010 - 6:00 PDT
| Patient / Public: | ![]() | |
| Healthcare Prof: | ![]() |
Drug maker GlaxoSmithKline (GSK) "plans to bolster earnings by selling to more people in middle-income countries after cutting prices in the world's poorest nations," Bloomberg/BusinessWeek reports.
"Our strategy is to grow our business in middle-income countries by increasing the volume of products we sell," GSK Chief Executive Andrew Witty said by e-mail, according to the news service. "Extending [GSK's] flexible pricing program for such nations would 'improve the affordability of our medicines, increase access for patients with lower income levels and be profitable for GSK,' he said."
Middle-income countries vary "in terms of economic status, demography and health-care infrastructure which can vary significantly," Witty explained, the news service continues. "Taking a single pricing approach would be difficult, inappropriate and inequitable," he added. The news service notes Witty did not name individual countries (Ghosh, 3/9).
The Hindu Business Line reports on GSK's rationale for the customized approach to pricing for middle-income countries (Datta, 3/9).
"The long-term purpose of the initiative is to make its medicines accessible to all income groups," Economic Times/India Times reports. "The strategy will be executed through a combination of alliances with local firms or reduction of prices of selective brands," according to the news paper (Singh/Kumar, 3/10). Economic Times/India Times also features an interview with Witty (Singh/Kumar, 3/10).
In related news, Witty was in Nashik, India, on Monday to dedicate a new factory that will produce "albendazole, part of a combination treatment used within the World Health Organization's (WHO) Global Programme to Eliminate Lymphatic Filariasis (LF)," according to a GSK press release. The new facility "is expected to deliver 300 million tablets" of albendazole this year, the press release notes (3/8).
This information was reprinted from globalhealth.kff.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Global Health Policy Report, search the archives and sign up for email delivery at globalhealth.kff.org.
© Henry J. Kaiser Family Foundation. All rights reserved.
Visit our pharma industry / biotech industry section for the latest news on this subject.
MLA
14 Feb. 2012. <http://www.medicalnewstoday.com/releases/181962.php>
APA
http://www.medicalnewstoday.com/releases/181962.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



